1. Histological outcome during long-term lamivudine therapy
Jules L. Dienstag, Robert D. Goldin, E.Jenny Heathcote, H.W.L. Hann, Mary Woessner, Sally L. Stephenson, Stephen Gardner, D.Fraser Gray, Eugene R. Schiff 
Gastroenterology 
Volume 124, Issue 1, Pages (January 2003)
DOI: /gast
Copyright © 2003 American Gastroenterological Association Terms and Conditions

2. Fig. 1
Study design showing the timing of biopsies and YMDD-variant HBV assessments.
Gastroenterology  , DOI: ( /gast )
Copyright © 2003 American Gastroenterological Association Terms and Conditions

3. Fig. 2
Change in necroinflammatory scores for all 3 biopsies for individual patients according to duration of YMDD-variant HBV. The panels on the left represent a comparison between the pretreatment biopsy and the biopsy obtained at the end of 12 months of randomized treatment; the panels on the right represent a comparison between the end-of-randomized treatment biopsy and the month-24 biopsy.
Gastroenterology  , DOI: ( /gast )
Copyright © 2003 American Gastroenterological Association Terms and Conditions

4. Fig. 3
Improvement in bridging fibrosis during lamivudine therapy—photographs (A) before (pre) and (B) after (post) therapy (patient with YMDD-variant HBV).
Gastroenterology  , DOI: ( /gast )
Copyright © 2003 American Gastroenterological Association Terms and Conditions

5. Fig. 4
Improvement in cirrhosis during lamivudine therapy—photographs (A) before (pre) and (B) after (post) therapy (patient with wild-type HBV).
Gastroenterology  , DOI: ( /gast )
Copyright © 2003 American Gastroenterological Association Terms and Conditions